MURTY PHARMACEUTICALS, INC.

MURTY PHARMACEUTICALS, INC. specializes in the development and current Good Manufacturing Practice (cGMP) production of controlled pharmaceutical substances for federal research and public health initiatives. The company delivers end-to-end pharmaceutical solutions, including stability testing, pellet formulation, and synthesis of Schedule II controlled substances such as morphine sulfate and methamphetamine hydrochloride for intravenous use. Their technical expertise spans process development, analytical validation, and scale-up manufacturing of complex drug products targeting substance abuse disorders, with demonstrated proficiency in maintaining strict regulatory compliance under FDA and DEA oversight. A key differentiator is their ability to execute high-integrity, mission-critical manufacturing and R&D tasks under long-term IDIQ contracts, ensuring consistent supply of compounds for government-funded clinical and forensic applications. The contractor maintains a consistent, long-standing relationship with the Department of Health and Human Services, delivering specialized pharmaceutical development and manufacturing services across multiple fiscal years. Their work supports HHS initiatives in substance abuse treatment, forensic toxicology, and drug policy research, often under time-sensitive, high-security protocols requiring validated batch documentation and chain-of-custody controls. MURTY PHARMACEUTICALS primarily operates under NAICS 541715, reflecting its focus on life sciences R&D with pharmaceutical manufacturing as a supporting function. This positions them as a niche provider bridging preclinical development and compliant production for government agencies requiring controlled substance handling. Their market role is that of a trusted, specialized contractor for sensitive pharmaceutical research requiring regulatory precision and operational security. The company is structured as a small business (2L) headquartered in Lexington, Kentucky, with no federal certifications on record. Their geographic presence is centralized, with operations tailored to meet the stringent logistics and compliance demands of federal life sciences contracts.